Design and synthesis of piperazine-based matrix metalloproteinase inhibitors

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 369-380

  Cheng, Menyan ^a   De, Biswanath ^a   Pikul, Stanislaw ^a   Almstead, Neil G ^a   Natchus, Michael G ^a   Anastasio, Melanie V ^a   McPhail, Sara J ^a   Snider, Catherine E ^a   Taiwo, Yetunde O ^a   Chen, Longyin ^a,b   Dunaway, C Michelle ^a   Gu, Fei ^a   Dowty, Martin E ^a   Mieling, Glen E ^a   Janusz, Michael J ^a   Wang Weigand, Sherry ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXAMIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ARTICLE; DRUG ABSORPTION; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CARTILAGE; CATTLE; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; PIPERAZINES; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0034628453     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990366q     Document Type: Article

References (28)

1. (a) Birkedal-Hansen, H.; Moore, W.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 1993, 4, 197-250.
2. (b) Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6, 212-125.
3. (c) Murphy, G.; Docherty, A. J. P. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell. Mol. Biol. 1992, 7, 120-125.
4. (d) Docherty, A. J. P.; Murphy, G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann. Rheum. Dis. 1990, 49, 469-479.
5. (e) Woessner, F. J. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB 1991, 5, 2145-2154.
6. (f) Woessner, F. J. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB 1991, 5, 2145-2154.
7. (a) Lohmander, L. S.; Hoerrner, L. A.; Lark. M. W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993, 36, 181-189.
8. (b) Dean, D. D.; Martel-Pelletier, J.; Howell, D. S.; Woessner, J. F. Evidence for Metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritis cartilage. J. Clin. Invest. 1989, 67, 678-685.
9. Beckett, R. P.; Whittaker, M. Matrix Metalloprotease Inhibitors. Exp. Opin. Ther. Patents 1998, 8, 259-282.
10. (a) Natchus, M. G.; Cheng, M.; Wahl, C. T.; Pikul, S.; Almstead, N. G.; Bradley, R. S.; Taiwo, Y. O.; Mieling, G. E.; Dunaway, C. M.; Snider, C. E.; McIver, J. M.; Barnett, B. L.; McPhail, S. J.; Anastasio, M. B.; De, B. Design and Synthesis of Conformationally constrained MMP Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2077-2080.
11. (b) Pikul, S.; McDow Dunham, K. L.; Almstead N. G.; De, B.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Rydel, T.; Dunaway, C. M.; Gu, F.; Mieling, G. E. Discovery of Potent, Achiral Matrix Metalloprotease Inhibitors. J. Med. Chem. 1998, 41, 3568-3571.
12. (c) Pikul, S.; McDow Dunham, K. L.; Almstead, N. G.; De, B.; Natchus, M. G.; Anastasio, M. V.; McPhail, S.; Snider, C. E.; Taiwo, Y. O.; Chen, L.; Dunaway, C. M.; Gu, F.; Mieling, G. E. Design and Synthesis of Phosphinamide-Based Hydroxamic Acids as Inhibitors of Matrix Metalloproteinases. J. Med. Chem. 1999, 42, 87-94.
13. Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, Synthesis and Biological Evaluation of Potent Thiazine and Thiazepine Based MMP Inhibitors. J. Med. Chem. 1999, 42, 4547-4562.
14. (a) MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Ziu, L. J.; Hu, S.-i.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V. S.; Parker, D. T. Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabits. J. Med. Chem. 1997, 40, 2525-2532.
15. (b) MacPherson, L. J.; Parker, D. T. Arylsulfonamido-substituted hydroxamic acids. European Patent Application EP 0 606 046 Al, 1993.
16. (c) Parker, D. T.; MacPherson, L. J.; Goldstein, R.; Justice, M. R.; Ziu, L. J.; Capparelli, M.; Whaley, L. W.; Boehm, C.; O'Byrne, E. M.; Goldberg, R. L.; Ganu, V. S. CGS27023A: A Novel Potent, and Orally Active Matrix Metalloprotease Inhibitor. 7th International Conference on the Inflammation Research Association, White Haven, PA, Sept. 25-29, 1994.
17. (a) Knight, C. G.; Wilenbrock, F.; Murphy, G. A. A Novel Coumarin-labeled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases. FEBS Lett. 1992, 296, 263-266.
18. (b) Also see Experimental Section for further details.
19. See Experimental Section for details of the in vitro intestinal permeability studies.
20. See Experimental Section for details of the cartilage explant assay.
21. Peng, S. X.; VonBargen, E. C.; Bornes, D. M.; Pikul, S. Permeability of Articular Cartilage to Matrix Metalloprotease Inhibitors. Pharm. Res. 1998, 15, 1414-1418. Additional note: It is understood that the physicochemical properties of bovine nasal cartilage and articular cartilage are different. This work is cited in order to convey a sense that small MMPIs are capable of penetrating cartilage matrix.
22. Kozaci, L. D.; Buttle, D. J.; Hollander, A. P. Degradation of the Type II Collagen, But Not Proteoglycan, Correlates with Matrix Metalloprotease Activity in Cartilage Explant Cultures. Arthritis Rheum. 1997, 40, 164-174.
23. For a comprehensive review, see: Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
24. See Babine and Bender review (p 1436), ref 14.
25. (a) Hibner, B.; Card, A.; Flynn, C.; Housley, T.; Wihelm, S.; Casazza, A. M. Bay 12-9566, a Novel, Biphenyl Matrix Metalloprotease Inhibitor, Demonstrates Anti-Invasive and Anti-Angiogenic Properties. American Association for Cancer Research, 89th Annual Meeting, New Orleans, 1998; Poster 2063.
26. (b) See the following for BB-2516 and other similar MMPIs: White, A. D.; Bocan, T. M. A.; Boxer, P. A.; Peterson, J. T.; Schrier, D. Emerging Therapeutic Advances for the Development of Second generation Matrix Metalloproteinase Inhibitors. Curr. Pharm. Des. 1997, 3, 45-58.
27. Chen, L.; Rydel, T. J.; Gu, F.; Dunaway, C. M.; Pikul, S.; Dunham, K. M.; Barnett, B. L. Crystal Structure of the Stromelysin Catalytic Domain at 2 ÅResolution: Inhibitor-induced Conformational Changes. J. Mol. Biol. 1999, in press.
28. Okada, Y.; Nagase, H.; Harris, E. D. A Metalloproteinase from Human Rheumatoid Synovial Fibroblasts that Digests Connective Tissue Matrix Components. Purification and Characterization. J. Biol. Chem. 1986, 261, 14245-14255.